1. What Is the Blue Hat and Why It Matters

The “Blue Hat” (蓝帽子, lán mào zi) is the colloquial name for China’s official health food approval mark — a blue, hat-shaped logo that appears on every legally sold health food product in China. Overseen by the National Medical Products Administration (NMPA) under the State Administration for Market Regulation (SAMR), the Blue Hat certifies that a product has passed rigorous safety, quality, and efficacy reviews. Without it, a product cannot be imported, advertised, or sold as a health supplement on the Chinese mainland.

For foreign supplement and nutraceutical companies, the Blue Hat is simultaneously the most valuable asset and the most formidable barrier to entry in China’s booming health supplement market, which was valued at over RMB 300 billion (≈ USD 42 billion) in 2025 and continues to grow at 8–10% annually. A Blue Hat registration grants manufacturers legal access to the world’s second-largest nutraceuticals market, enables e-commerce listings on Tmall Global, JD Worldwide, and Douyin, and provides a powerful trust signal to Chinese consumers who have grown increasingly health-conscious and brand-aware.

However, the process is neither quick nor cheap. Full registration can take 12 to 24 months, require tens of thousands of pages of documentation, and cost anywhere from $50,000 to $200,000 when factoring in testing, legal representation, and consultancy fees. Many foreign companies underestimate the complexity and suffer costly delays or outright rejections. This guide provides a complete, practical walkthrough of the Blue Hat registration process as it stands in 2026, covering the regulatory framework, step-by-step procedures, required documentation, timelines, costs, and recent policy updates that every foreign entrant must understand.

2. The Two-Track System: Registration vs. Filing

China’s health supplement regulatory system underwent a fundamental restructuring under the 2016 Administrative Measures for Health Food Registration and Filing, which created a bifurcated pathway. Understanding which track applies to your product is the single most important strategic decision you will make.

Health Food Registration (保健食品注册 — Bǎo Jiàn Shí Pǐn Zhù Cè)

Registration is the more rigorous pathway, reserved for products containing new ingredients not yet on the national list of health food ingredients (保健食品原料目录), or products making functional claims that require individual substantiation. Under this track, every aspect of the product — from raw material sourcing to manufacturing process to clinical evidence — is reviewed by the NMPA’s Technical Evaluation Center. Registration results in a Health Food Registration Certificate (保健食品注册证书), which is valid for five years and renewable. This is the path most foreign companies must follow, especially if they wish to bring proprietary formulations or novel ingredients into China.

Health Food Filing (保健食品备案 — Bǎo Jiàn Shí Pǐn Bèi Àn)

Filing is a significantly lighter administrative process available for products that use only ingredients from the National List of Health Food Ingredients (保健食品原料目录) and the List of Health Food Functional Claims. Filing is essentially a notification process: the manufacturer submits documentation confirming the product meets established standards, and the NMPA issues a Filing Acceptance Letter (备案凭证). The review is less intensive, turnaround is faster (typically 3–6 months), and costs are substantially lower. Filing is available to domestic manufacturers and certain importers, but in practice, foreign companies face significant restrictions on filing eligibility, which we cover in the next section.

3. Eligibility: Which Products Require Registration vs. Filing

Determining eligibility is not always straightforward. China’s regulatory framework categorizes products based on three dimensions: (a) ingredient status, (b) functional claim type, and (c) manufacturing location.

Ingredient Status

China maintains two positive lists: the Health Food Ingredient Catalog and the Health Food Raw Material Catalog. Ingredients on these lists have been pre-assessed for safety and, in some cases, for functional efficacy. If every ingredient in your product appears on these lists, you may be eligible for the filing pathway — otherwise, full registration is required.

Foreign Company Eligibility

Under current regulations, foreign manufacturers are generally not eligible for the simplified filing pathway unless they meet specific conditions. The 2016 Measures stipulate that only domestic manufacturers and products manufactured overseas using ingredients on the national list that are identical in specifications to domestically filed products can use filing. In practice, this means most foreign companies — especially those with proprietary formulations — must pursue full registration. There have been some pilot programs in free trade zones (e.g., Hainan Boao Lecheng) that offer filing-like pathways for certain imported products, but these remain limited in scope and product categories.

Products That Inherently Require Registration

• Products with new food ingredients not previously approved in China
• Products with new functional claims not on the standard list
• Combination products mixing Western nutraceutical ingredients with traditional Chinese medicine (TCM) herbs
• Products manufactured by foreign entities without a China-based manufacturing subsidiary
• Products with dosage forms not commonly recognized in China’s health food classification

Products Eligible for Filing (with caveats)

• Single-ingredient vitamin or mineral supplements on the national list
• Certain probiotics and omega-3 products that match published specifications exactly
• Products manufactured by a wholly foreign-owned enterprise (WFOE) in China with a local production facility

4. Registration Process Step-by-Step

The full registration process for a health supplement in China involves five major phases. Each phase has its own approval gates, and failure at any point means restarting or abandoning the application.

Phase A: Pre-Assessment and Testing (3–6 Months)

Before any application is submitted, the product must undergo a series of mandatory tests conducted by NMPA-accredited testing laboratories in China. These include:

• Toxicology safety assessment — acute, sub-chronic, and mutagenicity studies
• Functional efficacy testing — animal and/or human trials to substantiate claimed health benefits
• Stability testing — accelerated and long-term stability (typically 3–6 months of accelerated, 12–24 months of real-time)
• Quality specification testing — heavy metals, microbiological limits, pesticide residues, and contaminant analysis
• Product formula validation — verification that raw materials, dosages, and processing meet Chinese pharmacopeia or GB standards

Testing must be performed on three distinct production batches to demonstrate consistency. Foreign test reports are not accepted — all testing must be conducted in China or at least verified by a Chinese-accredited lab.

Phase B: Application Submission to NMPA (1–2 Months)

Once testing is complete, the applicant submits a comprehensive dossier to the NMPA’s Center for Health Food Evaluation (CFHE, under SAMR/NMPA). As of 2025–2026, submissions are made via the online e-submission platform, which was fully digitized under the 2024–2025 regulatory reforms. The submission includes all test reports, product specifications, manufacturing process descriptions, quality standards, and labeling artwork. A product sample (usually 10–30 units) must also be physically submitted for reference.

The NMPA will issue a Acceptance Notice or a Supplement Notice within 10–15 working days. If documents are incomplete, the application is returned with a list of deficiencies and the applicant has a limited window to resubmit.

Phase C: Technical Review (6–12 Months)

This is the longest and most intensive phase. A panel of scientific reviewers at the CFHE examines every aspect of the dossier. Key areas of scrutiny include:

• Ingredient safety and rationale — especially for novel ingredients or super-doses
• Functional claim substantiation — the scientific evidence must be robust; Chinese regulators prefer randomized controlled trials conducted on Chinese populations
• Manufacturing process consistency — critical process parameters and quality control points must be clearly documented
• Label and advertising claims — all claims must match the approved functional language exactly; no embellishment is permitted

During this phase, the CFHE may request supplementary data, which can extend the timeline by 3–6 months per request cycle. On average, technical review consumes 9 months of the total timeline.

Phase D: On-Site Inspection of Production Facility (2–3 Months)

If the dossier passes technical review, the NMPA dispatches a team of inspectors to conduct a Good Manufacturing Practice (GMP) audit of the production facility — whether in China or overseas. For foreign facilities, the NMPA works with local NMPA-authorized inspection agencies or conducts the inspection itself with advance coordination. The inspection checks:

• Compliance with China’s GB 17405-1998 Good Manufacturing Practice for Health Food (updated in 2024 as GB 17405-2024)
• Sanitation conditions, equipment calibration, and quality control laboratory setup
• Traceability from raw material intake to finished product dispatch
• Staff training, hygiene protocols, and documentation practices

Inspection findings are graded: Pass, Conditional Pass (with corrective actions required within 30–60 days), or Fail. A failed inspection means the entire registration is rejected and must be restarted from Phase A with a new application.

Phase E: Approval and Certificate Issuance (1–2 Months)

After the facility passes inspection and the CFHE completes its review, the application moves to final approval by the NMPA Commissioner. Once signed off, a Health Food Registration Certificate is issued. The certificate is valid for five years, after which a renewal application must be submitted at least six months before expiry. The Blue Hat logo (a blue oval with “保健食品” text and a dedicated registration number in the format Guo Shi Jian Zi G[Year]XXXX) can then appear on product packaging and marketing materials.

5. Required Documents

The documentation requirements for a Blue Hat registration are extensive. Below is a summary of the core documents required in the application dossier, many of which must be translated into Chinese by a certified translator and notarized.

Mandatory Documentation Checklist

1. Health Food Registration Application Form — standardized NMPA template, completed in Chinese
2. Letter of Authorization — if using a China-based agent, a notarized power of attorney
3. Product Formula and Bill of Materials — full quantitative composition with rationale for each ingredient’s inclusion and dosage
4. Manufacturing Process Description — step-by-step production flow, critical process parameters, in-process controls
5. Quality Standards and Specifications — raw material monographs, finished product specifications, analytical methods
6. Stability Testing Reports — accelerated (6 months at 40°C/75% RH) and long-term (24 months at 25°C/60% RH) data
7. Toxicology Safety Evaluation Report — conducted by NMPA-accredited lab, covering acute, sub-chronic, genotoxicity, and if applicable, developmental toxicity
8. Functional Efficacy Evaluation Report — animal and/or human clinical trial data substantiating the claimed health function
9. Packaging, Labeling, and Instruction Leaflet — final approved versions with all required disclosures, including the “This product is not a substitute for medicine” disclaimer
10. GMP Certificate or Equivalent — proof of manufacturing facility compliance with health food GMP standards
11. Product Samples — 10–30 commercial-scale batch units representing three distinct production batches
12. Free Sale Certificate and Certificate of Manufacture — issued by relevant authorities in the country of origin

6. Timeline: What to Expect

The total timeline from initial testing to Blue Hat issuance typically spans 13 to 25 months, with 18 months being a realistic planning estimate for most foreign companies. However, several factors can significantly extend this:

• Novel ingredient status: If any ingredient requires assessment by the National Health Commission (NHC) before NMPA can evaluate it, add 6–12 months
• Clinical trial requirements: If human efficacy trials are needed (vs. animal-only), budget an additional 6–9 months for trial design, ethical approval, enrollment, and analysis
• Supplementary data requests: Each round of questions from the CFHE typically adds 3–6 months
• Inspection scheduling: Overseas facility inspections depend on NMPA inspector availability; scheduling can add 2–4 months of lead time
• Seasonal factors: Applications submitted around Chinese New Year (January–February) or the National Day holiday (October) often see processing delays

For companies on the filing pathway (where eligible), timelines are dramatically shorter — typically 3 to 6 months from submission to filing acceptance. However, as discussed, this option is rarely available to foreign manufacturers with proprietary products.

7. Costs and Budgeting

The total cost of registering a health supplement in China varies widely based on product complexity, testing requirements, and whether you use a third-party consultant. Below is a realistic budget breakdown.

It is strongly recommended to work with an experienced China-based regulatory consultant who specializes in health food registration. The right consultant can reduce the risk of rejection, accelerate timelines by anticipating CFHE questions, and manage the relationship with testing labs and the NMPA. However, the cost of consultancy represents the single largest line item — expect to pay $25,000–$80,000 depending on the scope of services.

8. Permitted Functional Claim Categories

China strictly controls the health claims that can be made on health supplement products. The NMPA publishes an official list of approved functional claim categories, and every claim on your product label and marketing materials must be drawn from — and worded exactly as — one or more of these categories. As of the 2025 expansion of the functional claim list, the following 27 categories are permitted in 2026:

1. Enhances immunity  (增强免疫力)
2. Aids in lowering blood lipids  (辅助降血脂)
3. Aids in lowering blood sugar  (辅助降血糖)
4. Improves sleep  (改善睡眠)
5. Relieves visual fatigue  (缓解视疲劳)
6. Aids in memory improvement  (辅助改善记忆)
7. Promotes lead excretion  (促进排铅)
8. Promotes digestive health  (促进消化)
9. Aids in lowering blood pressure  (辅助降血压)
10. Alleviates physical fatigue  (缓解体力疲劳)
11. Improves bone density  (增加骨密度)
12. Protects against oxidative damage  (对辐射危害有辅助保护功能)
13. Improves skin health  (改善皮肤水分)
14. Promotes lactation  (促进泌乳)
15. Enhances anabolic metabolism  (促进生长发育)
16. Improves iron-deficiency anemia  (改善缺铁性贫血)
17. Aids in weight management  (有助于控制体重)
18. Supports gastric mucosal protection  (对胃黏膜有辅助保护功能)
19. Relieves throat discomfort  (缓解咽部不适)
20. Protects liver from chemical damage  (对化学性肝损伤有辅助保护功能)
21. Supports intestinal health  (有助于维持肠道健康)
22. Supports blood lipid health  (有助于维持血脂健康水平)
23. Supports blood sugar health  (有助于维持血糖健康水平)
24. Supports blood pressure health  (有助于维持血压健康水平)
25. Reduces body fat  (有助于减少体内脂肪)
26. Improves cognitive function  (有助于改善认知功能) — new in 2025
27. Supports joint health  (有助于维持关节健康) — new in 2025

9. Common Reasons for Rejection

Understanding why applications fail can save months of wasted effort. Based on NMPA denial data and consultant experience, the most common reasons for Blue Hat registration rejection include:

1. Insufficient safety data — particularly for novel ingredients. If toxicology studies show adverse effects at relevant doses, or if the safety margin is too narrow, the application is rejected outright.
2. Weak functional claim substantiation — Chinese regulators expect robust scientific evidence. Relying on traditional use claims or studies conducted on non-Chinese populations (without supporting local data) is a frequent cause of failure.
3. Inconsistencies across documentation — if the product formula in the application differs from the sample tested, or if the manufacturing process described does not match on-site observations, the application will be deemed unreliable.
4. Non-compliant labeling — claims that exceed the approved wording list, missing disclaimers, incorrect font sizes for mandatory text (Chinese law requires certain warnings to be at least a minimum point size), or using images that imply medicinal effects.
5. GMP deficiencies during on-site inspection — this is a hard stop. Common issues include inadequate water quality testing, insufficient traceability systems, and lack of environmental monitoring in production areas.
6. Incorrect product categorization — some products that resemble health supplements are actually classified as food for special medical purposes (FSMP) or as general food under Chinese law, leading to procedural mismatches.
7. Failure to respond to supplement notices within the deadline — the CFHE gives applicants a limited window (typically 30–60 days) to address deficiencies. Missing this deadline means the application is considered withdrawn.

To mitigate these risks, consider conducting a pre-submission gap analysis with a qualified regulatory consultant before committing to the full testing and application process.

10. 2026 Updates: Digitization, New Claim Categories, and What They Mean for You

2025 and 2026 have brought meaningful regulatory modernization to China’s health supplement framework. Here are the key developments that foreign companies need to know about.

Full Digitization of the Application Process

As of January 2025, all health food registration and filing applications must be submitted through the NMPA’s online e-submission platform (国家市场监督管理总局行政审批网上办理平台). Physical document submissions have been eliminated for the initial application stage, though product samples and certain original certificates must still be physically delivered. The digital system includes automated validation checks that flag incomplete submissions before they reach human reviewers, reducing the administrative rejection rate. However, the system is currently available only in Chinese, and foreign applicants must have a China-based legal entity or authorized agent with a verified digital certificate to access the platform.

Expanded Functional Claim Categories

The 2025 expansion added two new functional claim categories — “improves cognitive function” and “supports joint health” — after a decade without additions to the original 25. This signals a gradual opening to a wider range of health benefit claims and is particularly relevant for companies developing nootropic or joint-care products. However, the NMPA has made clear that these new categories come with stricter evidence requirements, including a preference for randomized, double-blind, placebo-controlled trials conducted on Chinese subjects.

Stricter Scrutiny on Overseas Production Facilities

In 2025, the NMPA announced that overseas facility inspections would increase in frequency and depth. Previously, many foreign facilities were audited only once during initial registration. Now, random follow-up inspections can occur at any time during the five-year certificate validity period. Additionally, the NMPA has expanded its mutual recognition agreements with certain countries (including some EU member states and ASEAN nations) for GMP certificates, which may streamline the inspection process for facilities in those jurisdictions.

Harmonization with International Standards

China continues to align certain health food standards with Codex Alimentarius and ISO 22000 frameworks. The updated GB 17405-2024 GMP standard incorporates elements of ISO 22000:2018 and the WHO GMP guidelines, making compliance more predictable for foreign manufacturers already certified under those international standards.

Implications for Foreign Companies Entering in 2026

The combination of digitization, expanded claims, and international harmonization is broadly positive for foreign supplement companies — the process is becoming more transparent and predictable. However, the increased scrutiny on facility inspections and the requirement for high-quality local clinical data mean that early planning and substantial investment in local partnerships remain essential. Companies that enter the market with a long-term perspective — building relationships with Chinese testing labs, regulatory consultants, and distribution partners — will fare significantly better than those seeking a quick market entry.